# 10x Genomics, Inc. – Consensus ‘buy’ rating and 52.0% Upside Potential

- Link: https://www.directorstalkinterviews.com/10x-genomics-inc.consensus-buy-rating-and-52.0-upside-potential/4121130281
- Published: 2023-10-20T12:30:32+01:00
- Author: Charlotte Edwards

**10x Genomics, Inc.** with ticker code (TXG) now have 12 confirmed analysts covering
the stock with the consensus suggesting a rating of ‘buy’. The range between the
high target price and low target price is between 75 and 30 calculating the mean
target price we have $60.33. Given that the stocks previous close was at $39.68 
this indicates there is a potential upside of 52.0%. The day 50 moving average is
$45.25 while the 200 day moving average is $50.25. The company has a market capitalization
of 4.67B. The stock price is currently at: 39.73 USD

 The potential market cap would be $7,092,753,666 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of -, revenue per share of 4.93 and
a -11.2% return on assets.

10x Genomics, Inc. is a life science technology company. The Company’s integrated
platform solutions include instruments, consumables and software for analyzing biological
systems. Its Chromium platform includes its Chromium X Series, Chromium Connect 
and legacy Chromium Controller instruments, microfluidic chips and related consumables,
enables throughput analysis of individual biological components. Its Visium platform
enables researchers to understand the spatial positions of biological analytes within
tissues at high resolution. Its products include Chromium Single Cell Gene Expression,
Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling,
Chromium Single Cell assay for transposase accessible chromatin (ATAC), Chromium
Single Cell Multiome ATAC + Gene Expression, Visium Spatial Gene Expression, Visium
Spatial Proteogenomics and Xenium In Situ Gene Expression. Its patent portfolio 
comprises over 1,750 issued patents and patent applications.

Share on: